Results 21 to 30 of about 732,435 (348)

Interethnic differences in pancreatic cancer incidence and risk factors: The Multiethnic Cohort. [PDF]

, 2019
While disparity in pancreatic cancer incidence between blacks and whites has been observed, few studies have examined disparity in other ethnic minorities. We evaluated variations in pancreatic cancer incidence and assessed the extent to which known risk
Haiman, Christopher A, Huang, Brian Z, Le Marchand, Loic, Monroe, Kristine R, Pandol, Stephen J, Setiawan, Veronica Wendy, Stram, Daniel O, Wilkens, Lynne R, Zhang, Zuo-Feng   +8 more
core   +1 more source

Efficacy of tumor-targeting Salmonella typhimurium A1-R in combination with anti-angiogenesis therapy on a pancreatic cancer patient-derived orthotopic xenograft (PDOX) and cell line mouse models. [PDF]

, 2014
The aim of the present study was to examine the efficacy of tumor-targeting Salmonella typhimurium A1-R treatment following anti-vascular endothelial growth factor (VEGF) therapy on VEGF-positive human pancreatic cancer.
Bouvet, Michael, Chishima, Takashi, Endo, Itaru, Hiroshima, Yukihiko, Hoffman, Robert M, Ichikawa, Yasushi, Maawy, Ali, Matsuyama, Ryusei, Miwa, Shinji, Momiyama, Masashi, Mori, Ryutaro, Murakami, Takashi, Sato, Sho, Tanaka, Kuniya, Yamamoto, Mako, Yano, Shuya, Zhang, Yong, Zhao, Ming   +17 more
core   +5 more sources

Combined resection of the transpancreatic common hepatic artery preserving the gastric arterial arcade without arterial reconstruction in hepatopancreatoduodenectomy: a case report

Surgical Case Reports, 2018
Background Surgeons sometimes must plan pancreatoduodenectomy (PD) for patients with a variant common hepatic artery (CHA) branching from the superior mesenteric artery (SMA) penetrating the pancreatic parenchyma, known as a transpancreatic CHA (tp-CHA).
Takashi Miyata, Yusuke Yamamoto, Teiichi Sugiura, Yukiyasu Okamura, Takaaki Ito, Ryo Ashida, Sunao Uemura, Yoshiyasu Kato, Katsuhisa Ohgi, Atsushi Kohga, Tsuneyuki Uchida, Shusei Sano, Katsuhiko Uesaka   +12 more
doaj   +1 more source

Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma

Journal of Hematology & Oncology, 2020
Pancreatic ductal adenocarcinoma (PDAC) is a malignancy characterized by a poor prognosis and high mortality rate. Genetic mutations and altered molecular pathways serve as targets in precise therapy.
Yunzhen Qian, Yitao Gong, Zhiyao Fan, Guopei Luo, Qiuyi Huang, Shengming Deng, He Cheng, Kaizhou Jin, Quanxing Ni, Xianjun Yu, Chen Liu   +10 more
doaj   +1 more source

Circular RNA CircEYA3 induces energy production to promote pancreatic ductal adenocarcinoma progression through the miR-1294/c-Myc axis

Molecular Cancer, 2021
Background Extensive studies have demonstrated the pivotal roles of circular RNAs (circRNAs) in the occurrence and development of different human cancers. However, the expression and regulatory roles of circRNAs in pancreatic ductal adenocarcinoma (PDAC)
Zeyin Rong, Si Shi, Zhen Tan, Jin Xu, Qingcai Meng, Jie Hua, Jiang Liu, Bo Zhang, Wei Wang, Xianjun Yu, Chen Liang   +10 more
doaj   +1 more source

Hypermutation In Pancreatic Cancer [PDF]

Gastroenterology, 2017
Pancreatic cancer is molecularly diverse, with few effective therapies. Increased mutation burden and defective DNA repair are associated with response to immune checkpoint inhibitors in several other cancer types. We interrogated 385 pancreatic cancer genomes to define hypermutation and its causes. Mutational signatures inferring defects in DNA repair
Ivana Cataldo, Andrew V. Biankin, Anirban Maitra, Anthony J. Gill, Anthony J. Gill, Anthony J. Gill, Andreia V. Pinho, Nikolajs Zeps, Richard D. Schulick, Marc D. Jones, Marc D. Jones, Oliver Hofmann, Timothy J. C. Bruxner, Felicity Newell, Felicity Newell, Skye McKay, John V. Pearson, John V. Pearson, Margaret A. Tempero, Jaswinder S. Samra, Jaswinder S. Samra, Conrad Leonard, Conrad Leonard, Ivon Harliwong, Marc Giry-Laterriere, Matthew J. Anderson, Andrew Barbour, Roberto Salvia, Fraser Duthie, Nicola Waddell, Nicola Waddell, Amanda Mawson, Oliver Holmes, Oliver Holmes, Peter J. Wilson, Ilse Rooman, Suzanne Manning, J. Lynn Fink, Giampaolo Tortora, Nick Waddell, Craig Nourse, Craig Nourse, Robert Grützmann, Angelika N. Christ, Nigel B. Jamieson, Nigel B. Jamieson, Karin A. Oien, C. Ross Carter, Jeremy L. Humphris, Venessa T. Chin, Christopher J. Scarlett, Christopher J. Scarlett, Peter Bailey, Peter Bailey, Christine A. Iacobuzio-Donahue, Rita T. Lawlor, Janet Graham, Janet Graham, Marina Pajic, Marina Pajic, Jennifer P. Morton, Ronald S Mead, Karin S. Kassahn, Karin S. Kassahn, David Miller, David Miller, Mark Pinese, Lorraine A. Chantrill, Lorraine A. Chantrill, David K. Chang, Angela Chou, Angela Chou, Stephen H. Kazakoff, Stephen H. Kazakoff, Owen J. Sansom, Krishna Epari, Nam Q. Nguyen, Ann-Marie Patch, Ann-Marie Patch, Elizabeth A. Musgrove, Elizabeth A. Musgrove, Elizabeth A. Musgrove, Andrew Stone, Christopher L. Wolfgang, Christian Pilarsky, Ehsan Nourbakhsh, Katia Nones, Katia Nones, Borislav Rusev, Neil D. Merrett, Jianmin Wu, Vincenzo Corbo, Senel Idrisoglu, Colin J. McKay, Ralph H. Hruban, Sean M. Grimmond, Sean M. Grimmond, Qinying Xu, Qinying Xu, Euan J. Dickson, Christopher W. Toon, Mark J. Cowley, Mark J. Cowley, Amber L. Johns, Adnan Nagrial, James R. Eshleman, James G. Kench, James G. Kench, James G. Kench, Aldo Scarpa, Jane Hair, Scott Wood, Scott Wood, Michael C.J. Quinn, Michael C.J. Quinn, Richard A. Morgan   +115 more
openaire   +5 more sources

Pancreatic cancer cachexia: a review of mechanisms and therapeutics. [PDF]

, 2014
Over the last decade, we have gained new insight into the pathophysiology of cachexia associated with pancreatic cancer. Unfortunately, its treatment is complex and remains a challenge.
Andrew Eugene Hendifar, Andrew Eugene Hendifar, Carlyn Rose Tan, Laith eJamil, Nick eNissen, Patrick eYaffee, Richard eTuli, Simon eLo, Stephen J Pandol   +8 more
core   +2 more sources

PARP inhibitors in pancreatic cancer: molecular mechanisms and clinical applications

Molecular Cancer, 2020
Pancreatic cancer is a highly lethal disease with a poor prognosis, and existing therapies offer only limited effectiveness. Mutation gene sequencing has shown several gene associations that may account for its carcinogenesis, revealing a promising ...
Heng Zhu, Miaoyan Wei, Jin Xu, Jie Hua, Chen Liang, Qingcai Meng, Yiyin Zhang, Jiang Liu, Bo Zhang, Xianjun Yu, Si Shi   +10 more
doaj   +1 more source

Mutant p53R270H drives altered metabolism and increased invasion in pancreatic ductal adenocarcinoma [PDF]

, 2018
Pancreatic cancer is characterized by nearly universal activating mutations in KRAS. Among other somatic mutations, TP53 is mutated in more than 75% of human pancreatic tumors.
Daylan, Ayse Ece Cali, Del Vecchio, Annachiara, Espinoza, Carlos, Fabo, Tania, Fearon, Eric R., Feng, Ying, Galbán, Stefanie, Halbrook, Christopher J., Karim, Saadia A., Kovalenko, Ilya, Kremer, Daniel M., Kumar-Sinha, Chandan, Lee, Ho-Joon, Ljungman, Mats, Lyssiotis, Costas A., Magnuson, Brian, Morton, Jennifer P., Pasca di Magliano, Marina, Schofield, Heather K., Yan, Wei, Zeller, Jörg   +20 more
core   +1 more source

The tumor-educated-macrophage increase of malignancy of human pancreatic cancer is prevented by zoledronic acid. [PDF]

, 2014
We previously defined macrophages harvested from the peritoneal cavity of nude mice with subcutaneous human pancreatic tumors as "tumor-educated-macrophages" (Edu) and macrophages harvested from mice without tumors as "naïve-macrophages" (Naïve), and ...
Bouvet, Michael, Chishima, Takashi, Endo, Itaru, Hassanein, Mohamed K, Hiroshima, Yukihiko, Hoffman, Robert M, Ichikawa, Yasushi, Maawy, Ali, Matsuyama, Ryusei, Menen, Rhiana, Miwa, Shinji, Momiyama, Masashi, Mori, Ryutaro, Murakami, Takashi, Tanaka, Kuniya, Uehara, Fuminari, Yamamoto, Mako, Yano, Shuya   +17 more
core   +8 more sources